Trial Profile
Study To Determine Efficacy of Aflibercept For Treatment Of Retinal Angiomatous Proliferation Secondary To Age Related Macular Degeneration
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 03 Feb 2020
Price :
$35
*
At a glance
- Drugs Aflibercept (Primary)
- Indications Age-related macular degeneration; Choroidal neovascularisation; Retinal haemorrhage; Retinal oedema
- Focus Therapeutic Use
- 03 Feb 2020 Status changed from recruiting to completed.
- 19 Mar 2015 New trial record